State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing a beneficial ownership position in SELLAS Life Sciences Group Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 10,373,074 shares of SELLAS Life Sciences Group Inc common stock.
  • Percent of class: The reported position represents 5.1% of the outstanding class of common stock.
  • Shared voting power: State Street reported shared voting power over 9,945,783 shares, with sole voting power of 0.
  • Shared dispositive power: The filing disclosed shared dispositive power over 10,373,074 shares, with sole dispositive power of 0.
  • Filing entity type: State Street Corporation is identified as a parent holding company (type "HC"), organized in Massachusetts.
  • Reporting subsidiaries: The position is held through subsidiaries including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each classified as an investment adviser (IA).

State Street Corporation's Schedule 13G Filing for SELLAS Life Sciences Common Stock

State Street Corporation, headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership in SELLAS Life Sciences Group Inc (CUSIP 81642T209) as of the event date of September 30, 2026. The filing was signed by Alok Maheshwary, Senior Vice President, and dated November 9, 2026. SELLAS Life Sciences Group Inc is located at 15 West 38th Street, 10th Floor, New York, New York, 10018, according to the filing.

According to the filing, State Street Corporation reported aggregate beneficial ownership of 10,373,074 shares, representing 5.1% of the class. The company disclosed 0 shares under sole voting power and 0 shares under sole dispositive power. Shared voting power was reported at 9,945,783 shares, while shared dispositive power covered the full 10,373,074 shares. The filing indicates that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

The filing identifies five subsidiaries through which the position is maintained, all classified as investment advisers: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing noted Items 5, 8, and 9 as "NOT APPLICABLE," indicating no group membership, no dissolution notice, and no ownership of 5% or less of a class.

What Was Disclosed

State Street Corporation disclosed a 5.1% beneficial ownership stake, totaling 10,373,074 shares, in SELLAS Life Sciences Group Inc common stock as of September 30, 2026, held through five investment adviser subsidiaries with no sole voting or dispositive power reported.